Literature DB >> 22442444

Inflammatory spleen monocytes can upregulate CD11c expression without converting into dendritic cells.

Scott B Drutman1, Julia C Kendall, E Sergio Trombetta.   

Abstract

Monocytes can differentiate into various cell types with unique specializations depending on their environment. Under certain inflammatory conditions, monocytes upregulate expression of the dendritic cell marker CD11c together with MHC and costimulatory molecules. These phenotypic changes indicate monocyte differentiation into a specialized subset of dendritic cells (DCs), often referred to as monocyte-derived DCs or inflammatory DCs (iDCs), considered important mediators of immune responses under inflammatory conditions triggered by infection or vaccination. To characterize the relative contribution of cDCs and iDCs under conditions that induce strong immunity to coadministered Ags, we analyzed the behavior of spleen monocytes in response to anti-CD40 treatment. We found that under sterile inflammation in mice triggered by CD40 ligation, spleen monocytes can rapidly and uniformly exhibit signs of activation, including a surface phenotype typically associated with their conversion into DCs. These inflammatory monocytes remain closely related to their monocytic lineage, preserving expression of CD115, scavenging function, tissue distribution and poor capacity for Ag presentation characteristic of their monocyte precursors. In addition, 3-4 d after delivery of the inflammatory stimuli, these cells reverted to a monocyte-associated phenotype typical of the steady state. These findings indicate that, in response to anti-CD40 treatment, spleen monocytes are activated and express certain DC surface markers without acquiring functional characteristics associated with DCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22442444      PMCID: PMC4594880          DOI: 10.4049/jimmunol.1102741

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity.

Authors:  S R Clarke
Journal:  J Leukoc Biol       Date:  2000-05       Impact factor: 4.962

2.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Dendritic cells continue to capture and present antigens after maturation in vivo.

Authors:  Scott B Drutman; E Sergio Trombetta
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

4.  Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs.

Authors:  Vadim Y Taraban; Tania F Rowley; Aymen Al-Shamkhani
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

5.  CD8 alpha alpha-mediated intraepithelial lymphocyte snatching of thymic leukemia MHC class Ib molecules in vitro and in vivo.

Authors:  Nathalie Pardigon; Kazuyo Takeda; Bertrand Saunier; Felicita Hornung; James Gibbs; Andrea Weisberg; Nikhat Contractor; Brian Kelsall; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

6.  Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes.

Authors:  Shalin H Naik; Donald Metcalf; Annemarie van Nieuwenhuijze; Ian Wicks; Li Wu; Meredith O'Keeffe; Ken Shortman
Journal:  Nat Immunol       Date:  2006-05-07       Impact factor: 25.606

7.  Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.

Authors:  Anna Charalambous; Margarita Oks; Godwin Nchinda; Sayuri Yamazaki; Ralph M Steinman
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

8.  Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

Authors:  Geertje J D van Mierlo; Zita F H M Boonman; Hélène M H Dumortier; Annemieke Th den Boer; Marieke F Fransen; Jan Nouta; Ellen I H van der Voort; Rienk Offringa; René E M Toes; Cornelis J M Melief
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

9.  CCR2 mediates homeostatic and inflammatory release of Gr1(high) monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection.

Authors:  Daniel R Engel; Juliane Maurer; André P Tittel; Christina Weisheit; Taner Cavlar; Beatrix Schumak; Andreas Limmer; Nico van Rooijen; Christian Trautwein; Frank Tacke; Christian Kurts
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

10.  Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.

Authors:  Laura Bonifaz; David Bonnyay; Karsten Mahnke; Miguel Rivera; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

View more
  18 in total

1.  Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes.

Authors:  Claudia Jakubzick; Emmanuel L Gautier; Sophie L Gibbings; Dorothy K Sojka; Andreas Schlitzer; Theodore E Johnson; Stoyan Ivanov; Qiaonan Duan; Shashi Bala; Tracy Condon; Nico van Rooijen; John R Grainger; Yasmine Belkaid; Avi Ma'ayan; David W H Riches; Wayne M Yokoyama; Florent Ginhoux; Peter M Henson; Gwendalyn J Randolph
Journal:  Immunity       Date:  2013-09-05       Impact factor: 31.745

2.  Antigen-specific regulation of IgE antibodies by non-antigen-specific γδ T cells.

Authors:  Yafei Huang; M Kemal Aydintug; Joshua Loomis; Megan K Macleod; Amy S McKee; Greg Kirchenbaum; Claudia V Jakubzick; Ross M Kedl; Deming Sun; Jordan Jacobelli; Rebecca L O'Brien; Willi K Born
Journal:  J Immunol       Date:  2012-12-28       Impact factor: 5.422

3.  Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes.

Authors:  Nadine Santana-Magal; Diana Rasoulouniriana; Corey Saperia; Amit Gutwillig; Peleg Rider; Edgar G Engleman; Yaron Carmi
Journal:  J Vis Exp       Date:  2018-05-31       Impact factor: 1.355

4.  Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.

Authors:  Peer W F Karmaus; Weimin Chen; Robert Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2012-11-14       Impact factor: 4.849

5.  The role of dendritic cells in the generation of CD4(+) CD25(HI) Foxp3(+) T cells induced by amino acid copolymers.

Authors:  Norio Kawamoto; Hidenori Ohnishi; Naomi Kondo; Jack L Strominger
Journal:  Int Immunol       Date:  2012-09-11       Impact factor: 4.823

6.  Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infection.

Authors:  Jonathan A Trujillo; Erica L Fleming; Stanley Perlman
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

7.  Transgene expression in various organs post BM-HSC transplantation.

Authors:  Nan Wang; Narendiran Rajasekaran; Tieying Hou; Elizabeth D Mellins
Journal:  Stem Cell Res       Date:  2013-11-02       Impact factor: 2.020

8.  Stromal cell induction of regulatory dendritic cells.

Authors:  Benjamin M J Owens; Paul M Kaye
Journal:  Front Immunol       Date:  2012-08-21       Impact factor: 7.561

9.  Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy.

Authors:  Marka R Crittenden; Benjamin Cottam; Talicia Savage; Cynthia Nguyen; Pippa Newell; Michael J Gough
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.